PD-L1: IO103

PD-1 and its ligand PD-L1 constitute an important immune regulatory pathway. The interaction between PD-1 and PD-L1 negatively regulates the proliferation and cytokine production of T-cells. Accordingly, cancers upregulate PD-L1 to evade the host immune system and PD-L1 expression is correlated with increased tumor aggressiveness and poor prognosis. PD-L1 expression has been reported for both hematological cancer and solid tumors.

Our fully owned program IO103 is a first-in-class, immune modulatory vaccine containing a single PD-L1-derived peptide designed to engage and activate PD-L1 specific human anti-regulatory T-cells.

IO103 is being tested in a single clinical trial:

  • A single arm phase IIa trial assessing IO103 as monotherapy in patients with Basal Cell Carcinoma of the skin (NCT03714529).

 Publications

PD-L1-specific T cells
Cancer Immunol Immunotherapy, January 2016

Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway
Leukemia, January 2014

HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients.
Cancer Research, March 2013